Abstract
With advances in our understanding of the genetics of pheochromocytomas and paragangliomas (PPGL), the answer to the question 'Should we search for a germline defect in patients diagnosed with PPGL?' has changed considerably since the end of the last century, when PPGL was thought to be inherited in only 10% of cases, because we now know that about 40% of patients carry a germline mutation in one PPGL susceptibility gene. PPGL is now considered to be the most highly heritable neuroendocrine tumour, with more than 15 susceptibility genes identified, and current guidelines recommend genetic testing during initial tests on PPGL patients. This genetic testing is routinely carried out by next-generation sequencing methods, making it possible to genotype a large number of susceptibility genes in a single analysis. Positive results for any of the known susceptibility genes are an indication for specific follow-up of the inherited disease and for the organization of predictive genetic testing in the patient's relatives. The development of precision medicine for PPGL, based on the molecular profile of the tumor, should become possible in the near future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
